Prostate Specific Antigen News and Research

RSS

Screening younger men at risk of prostate cancer can reduce metastatic cancer and deaths

Screening younger men and men at risk of prostate cancer can be beneficial in reducing metastatic cancer and deaths and should not be abandoned, states an article published in CMAJ (Canadian Medical Association Journal).

8 May 2012

CNV in prostate cancer tumors may accurately predict relapse

While active monitoring of serum prostate specific antigen (PSA) levels in men over 50 has greatly improved early detection of prostate cancer, prediction of clinical outcomes after diagnosis remains a major challenge.

7 May 2012

Researchers separate low and high-PSA prostate cancer cells

Prostate cancer cells that defy treatment and display heightened tumor-generating capacity can be identified by levels of prostate specific antigen (PSA) expressed in the tumor cells, a research team led by scientists at The University of Texas MD Anderson Cancer Center reports in the May 3 edition of Cell Stem Cell.

7 May 2012

Prostate cancer diagnosis on the rise among U.K. men

Latest figures from Cancer Research UK reveal that the number of men diagnosed with prostate cancer in the UK has risen above 40,000.

4 May 2012

FDA clears ProUroCare’s new prostate mechanical imaging system

ProUroCare Medical Inc., provider of proprietary medical imaging products, announced today it has received clearance from the U.S. Food & Drug Administration (FDA) for its ProUroScan prostate mechanical imaging (PMI) system.

2 May 2012

Studies: Against best advice, docs continue unneeded prostate screenings

JAMA and another journal found that despite government recommendations, doctors continue to screen too many men for prostate cancer.

26 Apr 2012

Prostate cancer screening recommendations not heeded by 44% men: Survey

81-year-old billionaire Warren Buffett was diagnosed with prostate cancer after having the finding initially detected through a screening blood test to measure a cancer marker called prostate specific antigen or PSA.

25 Apr 2012

Testosterone may help heart failure patients: Study

The researchers used testosterone patches and injections that improved the breathing and exercise abilities of people with heart failure, a chronic inability of the heart to pump enough blood to the rest of the body. Although most of the study participants were men, the researchers said the results would likely apply to women as well, through much smaller doses of testosterone.

18 Apr 2012

Two CNVs may increase risk of aggressive prostate cancer

An international research team led by Weill Cornell Medical College investigators have discovered two inherited-genetic deletions in the human genome linked to development of aggressive prostate cancer.

10 Apr 2012

New dietary supplement may arrest, lower rising PSA in men with recurrent prostate cancer

Preliminary findings from an FDA-approved clinical trial indicate that the experimental dietary supplement Prostate Health Cocktail (PHC) may arrest and in some cases lower rising PSA (Prostate Specific Antigen) in men with recurrent prostate cancer.

9 Apr 2012

Galeterone safe, effective for patients with CRPC

Patients with castration-resistant prostate cancer had limited side effects and in many cases a drop in prostate-specific antigen expression with galeterone (TOK-001), a small-molecule oral drug, according to phase I data presented at the AACR Annual Meeting 2012, held here March 31 - April 4.

2 Apr 2012

Tokai Pharmaceuticals announces data from galeterone Phase 1 trial for CRPC

Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that its lead candidate galeterone (TOK-001) was well-tolerated with minimal side effects and demonstrated efficacy in patients with castration-resistant prostate cancer (CRPC) in a Phase 1 study.

2 Apr 2012

Guidelines for cervical cancer screening revised

The guidelines say that women between 30 and 65 can wait five years between screenings if they get both a Pap test and an HPV test.

16 Mar 2012

Prostate cancer screening debate continues

Routine tests that help detect prostate cancer actually do reduce the risk of death from the disease, researchers said. Screening is done with a simple blood test that measures levels of prostate-specific antigen, or PSA.

15 Mar 2012

Gen-Probe receives FDA approval for PROGENSA PCA3 assay

DiagnoCure, Inc., a Quebec life sciences company that develops and commercializes high‐value cancer diagnostic tests, announced today that the US Food and Drug Administration (FDA) has approved Gen-Probe's PROGENSA PCA3 (Prostate Cancer Antigen 3) assay, the first molecular test to help determine the need for repeat prostate biopsies in men who have had a previous negative biopsy.

15 Feb 2012

Positive updated results from Aeterna Zentaris' AEZS-108 Phase 1 trial on CRPC

Aeterna Zentaris Inc. today reported positive updated results for the Phase 1 portion of its ongoing Phase 1/2 study in castration- and taxane-resistant prostate cancer (CRPC) with AEZS-108 (zoptarelin doxorubicin), the Company's targeted cytotoxic luteinizing hormone-releasing hormone (LHRH) analog.

4 Feb 2012

Novel PSAV risk count testing may effectively screen men for prostate cancer

A new study by NYU Langone Medical Center and Northwestern University Feinberg School of Medicine shows novel PSA velocity (PSAV) risk count testing may provide a more effective way for physicians to screen men for clinically significant prostate cancer.

3 Feb 2012

Preliminary results from CINJ's Celebrex and Lipitor Phase II combination trial on prostrate cancer

Research from The Cancer Institute of New Jersey (CINJ) on the FDA-approved drugs Celebrex and Lipitor -- used respectively for arthritis pain and lowering cholesterol -- shows that these drugs are well tolerated in the treatment of recurrent prostate cancer.

1 Feb 2012

Size of a man's prostate gland may determine severity of cancer

The size of a man's prostate gland may help predict the severity of cancer, with a smaller prostate being more likely to harbor serious disease.

31 Jan 2012

Dutaseride may help prevent progression of early stage prostate cancer: Study

A new study suggests that men with early stage prostate cancer may benefit with drugs that can slow or stop the cancer’s progress. Less than 10 percent of the 100,000 men each year who are diagnosed with early-stage prostate cancer and have the option of leaving the cancer in place. Rest get it removed using surgery or radiation. But those treatments can have serious side effects like impotence and incontinence.

24 Jan 2012